LAVA Therapeutics NV
LVTX
Market Cap$33.67M
Close$
$-2.51
298% downside
Current Fair Value
298% downsideOvervalued by 298% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $33.67 Million |
|---|---|
| Enterprise Value | $3.94 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.94 |
| Beta | 0.45 |
| Outstanding Shares | 26,866,931 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.37 |
|---|---|
| PEG | -3.5 |
| Price to Sales | - |
| Price to Book Ratio | 1.27 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | -0.16 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.34 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About LAVA Therapeutics NV
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The...